WASHINGTON — President Biden’s vision for an ambitious new government research center is never quite the same. He’s said it will focus on diabetes and Alzheimer’s. He told a prominent ALS advocate that the agency would focus on his disease, too. Once, he mentioned obesity. And, of course, there is his most common refrain: that the new research branch will “end cancer as we know it.”
The shifting vision is creating a lobbying frenzy among patient advocacy groups frustrated with the pace of research, all now scrambling to ensure they benefit from the gold rush of new research dollars and high-profile attention.
Create a display name to comment
This name will appear with your comment